Sustained Efficacy and Safety of Mirikizumab Through 152 Weeks in Chinese Patients with Moderately to Severely Active Crohn's Disease: A Subpopulation Analysis of the VIVID-1 and VIVID-2 Phase 3 Trials.
Xiang Gao
Qian Cao
Xiao-Wei Liu
Bai-Li Chen
Wen-Jia Liu
Wen Tang
Yu-Fang Wang
Jie Zhong
Zhao-Tao Li
Xiao-Yang Wang
Yi-Ci Sun
Prashant K. Gupta
Jiao Yu
Jia-Wei Xu
Min-Hu Chen
Medicine